𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Active and passive immunotherapy: vaccines and antibodies

✍ Scribed by Egbert Oosterwijk; Chaitanya Divgi; Neil H. Bander

Book ID
109053210
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
212 KB
Volume
99
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Fungal vaccines and immunotherapy
Fungal vaccines and immunotherapy
✍ E. Segal; D. Elad πŸ“‚ Article πŸ“… 2006 πŸ› Masson Editeur 🌐 French βš– 671 KB
Update on active specific immunotherapy
Update on active specific immunotherapy with melanoma vaccines
✍ Conforti, Arnold M.; Ollila, David W.; Kelley, Mark C.; Gammon, Guy; Morton, Don πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 113 KB πŸ‘ 2 views

Although a randomized clinical trial has yet to show a statistically significant improvement in the survival of patients receiving vaccine therapy for malignant melanoma, several studies have shown enhanced survival of patients developing an immune response to a melanoma vaccine. The knowledge and t

Antigen-specific immunotherapy and cance
Antigen-specific immunotherapy and cancer vaccines
✍ Elke JΓ€ger; Dirk JΓ€ger; Alexander Knuth πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 70 KB

The specific activation of the immune system to control cancer growth in vivo has been a long-standing goal in cancer immunology and medical oncology. The identification of tumor-associated antigens has provided the basis for new concepts in antigen-specific immunotherapy. The first clinical trials

Overview of melanoma vaccines: Active sp
Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients
✍ David W. Ollila; Mark C. Kelley; Guy Gammon; Donald L. Morton πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 96 KB πŸ‘ 2 views

Although a phase III trial has yet to show a statistically significant improvement in the disease-free or overall survival of melanoma patients receiving vaccine therapy, several phase II trials have shown enhanced disease-free and overall survival of patients who develop a humoral and/or cellular r